In the last 20 years, glucagon-like peptide-1 receptor agonists (GLP-1RA) have been used as one of the recommended pharmacotherapy options for individuals with type 2 diabetes mellitus, especially for large subgroups of patients with high cardiovascular risk and other comorbidities such as chronic kidney disease [1]. The gene discussed is GLP1R; the disease is diabetes mellitus.